Loading...
Caribou Biosciences Q4 2024 Earnings Report
Caribou Biosciences reported its fourth quarter and full year 2024 financial results, with a net loss of $35.5 million and total operating expenses of $41.0 million for the quarter.
Key Takeaways
Caribou Biosciences reported a net loss of $35.5 million for Q4 2024, compared to a net loss of $34.5 million in Q4 2023. Total operating expenses were $41.0 million, with cash, cash equivalents, and marketable securities at $249.4 million as of December 31, 2024.
Net loss for Q4 2024 was $35.5 million, an increase from $34.5 million in Q4 2023.
Total operating expenses for Q4 2024 were $41.0 million, slightly down from $41.0 million in Q4 2023.
Cash, cash equivalents, and marketable securities stood at $249.4 million as of December 31, 2024, expected to fund operations into H2 2026.
Licensing and collaboration revenue decreased to $2.1 million in Q4 2024 from $3.6 million in Q4 2023.
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences Revenue by Segment
Revenue by Segment
Licensing and collaboration Revenue
CapyFin.com Forward Guidance
Caribou Biosciences anticipates significant clinical data disclosures and advancements in its pipeline programs in the first half of 2025, with a pivotal Phase 3 clinical trial for CB-010 planned for H2 2025, pending FDA agreement.
Positive Outlook
- Expected clinical data disclosures for CB-010 ANTLER and CB-011 CaMMouflage in H1 2025.
- Planning to initiate a pivotal Phase 3 clinical trial for CB-010 in H2 2025, if data confirms initial observations.
- Continued enrollment in the ANTLER Phase 1 trial for CB-010 in 2L LBCL and CD19-targeted therapy relapsed patients.
- Rapid enrollment of additional patients in the CaMMouflage Phase 1 trial for CB-011 with deeper lymphodepletion.
- Activating sites for the GALLOP Phase 1 clinical trial for CB-010 in lupus.
Challenges Ahead
- Pivotal Phase 3 trial initiation for CB-010 is contingent on data confirmation and FDA agreement.
- Clinical outcomes may differ as patient enrollment continues and more data becomes available.
- Preclinical study results may not be borne out in human patients.
- Ability to obtain key regulatory input and approvals is a risk.
- Risks related to limited operating history and ability to raise additional capital.